Prollenium Medical Technologies, Inc. appears in FDA device records as the applicant behind PMA P160042, filed under product code LMH for an implant, dermal, for aesthetic use, device class 3. The original approval, for Revanesse Ultra, carries a decision date of August 4, 2017. Later supplements extend the same PMA to additional trade names and to manufacturing and supplier changes, so the public record shows one approval lineage rather than a set of separate applications. The supplied collection holds two linked PMA records, one approval and one 30-day notice, which is a snapshot of those filings and not a measure of total portfolio or commercial activity. [1][2][4]
The original approval and its stated indication
The earliest record in the collection is PMA P160042 for REVANESSE ULTRA, decided August 4, 2017, with a receipt date of September 22, 2016 and a Federal Register notice date of August 7, 2017. The approval order states the device is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more. The advisory committee is listed as General, Plastic Surgery, and the expedited review flag is recorded as N. [2]
A later FDA summary document identifies the original PMA for Revanesse Versa as having been approved on August 4, 2017, the same decision date recorded for P160042. That summary describes the device generic name as injectable dermal filler and lists the applicant address as 138 Industrial Parkway N., Aurora, ON, Canada. The address appears in a regulatory filing and is not treated here as a verified corporate headquarters. [4]
Supplement activity and product scope
PMA P160042/S010 covers Revanesse Lips+, described in the professional instructions for use as an injectable hyaluronic acid gel with 0.3% lidocaine. The same document characterizes the product as a biocompatible, biodegradable, non-pyrogenic, sterile, injectable viscoelastic clear colorless hydrogel based on bioresorbable BDDE cross-linked hyaluronan at a stated concentration of 22 to 28 mg/mL, containing 0.3% lidocaine. It is supplied in a glass syringe with a Luer-Lok fitting, packed with two 1.0 mL syringes and two sterilized 27 G x ½ inch needles in a peel tray within a carton, and includes a patient record label for traceability. [6]
The most recent record in the collection is P160042/S032, a 30-Day Notice received September 15, 2026 and decided October 14, 2026 under decision code OK30. Its approval statement covers qualification of a Third-Party Logistics supplier for warehousing and temperature-controlled storage of Revanesse Versa, Revanesse Versa+ and Revanesse Lips+ finished products, and the supplement reason is recorded as a process change affecting manufacturer, sterilizer, packager or supplier. The trade name field for this supplement lists Revanesse Versa, Revanesse Versa+ (with lidocaine) and Revanesse Lips+ (with lidocaine). [1]
What the public record does and does not establish
Across the supplied filings, the named products are Revanesse Ultra, Revanesse Versa, Revanesse Versa+ and Revanesse Lips+, all under the single PMA number P160042 and product code LMH. The collection's decision counts show one approval and one 30-day notice across two linked PMA records; those figures describe the supplied filings only and are not evidence of total company sales, total portfolio breadth or safety performance. No recall records appear in the supplied sample. [1][2]
Several details remain unknown from these sources. The filings do not establish ownership by a parent company, corporate headquarters, customer relationships, certifications beyond the quality system compliance statement in the 2020 summary, or commercial availability in any market. The Revanesse website pages in the collection present patient and provider information for Versa+ and Lips+ and carry a 2026 Prollenium copyright line, but they do not supply the missing corporate facts. [4][5][10]


